Litcius/Paper detail

Circulating Biomarkers in Hypertrophic Cardiomyopathy

Eldon Matthia, Michael L. Setteducato, Mohammed Elzeneini, Nicholas Vernace, Michael Salerno, Christopher M. Kramer, Ellen C. Keeley

2022Journal of the American Heart Association53 citationsDOIOpen Access PDF

Abstract

Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.

Topics & Concepts

MedicineHypertrophic cardiomyopathyCardiologyFibrosisCardiomyopathyMuscle hypertrophyInflammationMyocardial fibrosisMyocardial hypertrophyInternal medicineDiseaseBiomarkerPathologyHeart failureChemistryBiochemistryCardiomyopathy and Myosin StudiesGalectins and Cancer BiologyViral Infections and Immunology Research
Circulating Biomarkers in Hypertrophic Cardiomyopathy | Litcius